Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Krystal Biotech (NASDAQ:KRYS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.
Analyst Recommendations
This is a breakdown of recent ratings for Connect Biopharma and Krystal Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
| Krystal Biotech | 0 | 2 | 10 | 2 | 3.00 |
Connect Biopharma presently has a consensus target price of $6.14, indicating a potential upside of 550.24%. Krystal Biotech has a consensus target price of $377.20, indicating a potential upside of 16.22%. Given Connect Biopharma’s higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Krystal Biotech.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 991.46 | -$55.48 million | ($1.19) | -0.79 |
| Krystal Biotech | $389.13 million | 24.69 | $204.83 million | $7.98 | 40.67 |
Krystal Biotech has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Connect Biopharma has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
Insider & Institutional Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Connect Biopharma and Krystal Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -165.41% | -121.58% |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
Summary
Krystal Biotech beats Connect Biopharma on 12 of the 15 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
